Therapeutics for the induction of endogenous steroidogenesis and methods associated with their identification
The present disclosure provides agents capable of promoting endogenous steroid production (such as endogenous testosterone production) without altering the endogenous luteinizing hormone. The present disclosure also provides associated therapeutic methods as well as screening assays for identifying further therapeutic agents for the prevention, treatment and/or alleviations of symptoms associated with hypogonadism.
1. An isolated peptide consisting of a maximum of 13 consecutive amino acid residues and having the amino acid sequence RVTQSNF (SEQ ID NO: 5).
2. The isolated peptide of claim 1 , consisting of the amino acid sequence SKSRVTQSNFAVG (SEQ ID NO: 30).
3. The isolated peptide of claim 1 , consisting of the amino acid sequence AKSRVTQSNFAVG (SEQ ID NO: 31).
4. The isolated peptide of claim 1 , wherein the serine residue at position 5 of SEQ ID NO: 5 is phosphorylated.
5. A chimeric peptide having the isolated peptide of claim 1 fused to a cell penetrating peptide.
6. The chimeric peptide of claim 5 , wherein the cell penetrating peptide is from a TAT protein.
7. The chimeric peptide of claim 6 , wherein the cell penetrating peptide has the amino acid sequence YGRKKRRQRRR (SEQ ID NO: 29).
8. The chimeric peptide of claim 5 , wherein the carboxy terminus of the cell penetrating peptide is fused to the amino terminus of the isolated peptide.
9. The chimeric peptide of claim 5 , wherein the isolated peptide is fused to the cell penetrating peptide by a linker.
10. The chimeric peptide of claim 9 , wherein the linker comprises at least one amino acid.
11. The chimeric peptide of claim 10 , wherein the linker is a glycine residue.
12. A method for promoting the endogenous production of a steroid in a cell, said method comprising contacting the cell with the isolated peptide of claim 1 so as to promote the endogenous production of the steroid in the cell.
13. The method of claim 12 , wherein the steroid is testosterone.
14. The method of claim 12 , wherein the cell is in vivo and the method further comprises administering the isolated peptide, to a subject in need thereof comprising the cell.
15. The method of claim 14 , wherein the subject is a mammal.
16. The method of claim 15 , wherein the subject is a male.
17. The method of claim 12 , wherein the cell is from a testis.
18. The method of claim 17 , wherein the cell is a Leydig cell.
19. The method of claim 12 for the treatment and/or alleviation of symptoms of a condition associated with hypogonadism.
20. The method of claim 19 , wherein the condition associated with hypogonadism is at least one of infertility, aging, decreased libido, sexual dysfunction, altered mood, fatigue, decreased lean body mass, decreased bone mineral density, increased visceral fat or metabolic syndrome.